Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Thyroid Nodule 2Pain 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Agnosia 2Prostatic Neoplasms 1Neuroma 1Neuralgia 1Neoplasm Metastasis 1Myoma 1Multiple Pulmonary Nodules 1Multiple Advanced Tumors After PD-1 Therapy Failure 1Menorrhagia 1Lymphoma, Follicular 1Lipoma 1Leiomyoma 1Hypesthesia 1Hyperthyroidism 1Hyperaldosteronism 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cicatrix 1Carcinoma, Renal Cell 1Breast Cancer Female 1Bone Cancer Metastatic 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1ACTH Syndrome, Ectopic 1

Interventions

Specimen Handling 4Endoscopy 3Biopsy 3Itraconazole 2Endoscopy, Digestive System 2Diagnostic Imaging 2plecanatide 1obeticholic acid 1linaclotide 1Spectrum Analysis 1Sampling Studies 1Risk Assessment 1Radiofrequency Ablation 1Mass Screening 1Hematologic Tests 1Gastroscopy 1Endoscopic Mucosal Resection 1Cryosurgery 1Cetuximab 1Breath Tests 1Bevacizumab 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Barrett Esophagus × Radiofrequency Ablation × 1 year × Clear all
NCT06732388 2026-05-13

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
64 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡